Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
2 studies found for:    19952961 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Not yet recruiting Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in AML Patient Not Eligible for Transplant
Condition: Acute Myeloid Leukemia
Interventions: Drug: Fludarabine;   Drug: Melphalan;   Drug: Pembrolizumab
2 Unknown  Safety and Immunogenicity of Recombinant WT1 Antigen-Specific Cancer Immunotherapeutic Combined With Infusion of Treg Depleted T Cells for Adult WT1 Acute Myeloid Leukemia
Conditions: Acute Myelogenous Leukemia;   Myeloid Leukemia in Remission;   Effects of Immunotherapy
Intervention: Biological: Recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI)

Indicates status has not been verified in more than two years